Sandoz has announced that it has entered into a partnership with Taiwan-based biotechnology manufacturing and development company EirGenix, Inc, for a proposed trastuzumab biosimilar referencing Herceptin.
Sandoz has announced that it has entered into a partnership with Taiwan-based biotechnology manufacturing and development company EirGenix, Inc, for a proposed trastuzumab biosimilar referencing Herceptin.
Under the terms of the deal, EirGenix will develop and manufacture the biosimilar, while Sandoz will commercialize the product upon approval in all markets other than China and Taiwan. EirGenix will receive an upfront payment, milestone payments, and a share of profits from the biosimilar.
Sandoz indicated in a statement that this collaboration will allow the company to use its in-house resources to perpetuate its internal pipeline while further expanding its oncology portfolio and developing its hospital presence.
“Every year, approximately 300,000 people worldwide are diagnosed with HER2-positive breast cancer, which tends to spread more quickly than HER2-negative tumors, making swift treatment important. While targeted therapy is available, high out-of-pocket costs lead to limited treatment in the [United States,] and reimbursement issues have resulted in varying uptake in Europe,” said Stefan Hendriks, global head of biopharmaceuticals for Sandoz, in a statement. “Introducing biosimilars can help create earlier and expanded access to this important medicine, which is why I am so excited about the potential for this collaboration.”
The proposed biosimilar, EG12014, is currently in phase 3 clinical development, and EirGenix reports that the phase 3 trial in patients with breast cancer, begun in October 2018, will enroll a total of 800 patients. Patients will receive epirubicin and cyclophosphamide followed by either EG12014 or its reference plus paclitaxel. All patients will be scheduled for surgery 3 to 6 weeks after completion of neoadjuvant chemotherapy. The primary end point analysis is expected to be completed in the second half of 2020.
In May 2017, the company announced that the proposed biosimilar had demonstrated bioequivalence in a phase 1 clinical trial. The study was a double-blind, randomized, parallel group, 3-arm study in 84 healthy male volunteers. The study investigated the pharmacokinetic (PK) similarity between EG12014 and EU- and US-licensed reference Herceptin. According to the company, the study met its primary PK end point.
EirGenix also reports that it is developing a pertuzumab biosimilar referencing Perjeta, a bevacizumab biosimilar referencing Avastin, and an undisclosed biosimilar—all of which are in the preclinical phase—as well as novel drug agents.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.